Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Quince Therapeutics ( (QNCX) ) just unveiled an update.
On March 17, 2026, Quince Therapeutics, Inc. was notified by the Nasdaq Listing Qualifications Department that it had failed to maintain the required minimum market value of listed securities of $50 million over 30 consecutive business days, putting its continued listing on the Nasdaq Global Market at risk. On May 20, 2026, Nasdaq staff informed the company that, based on its March 31, 2026 quarterly report showing stockholders’ equity of $15.7 million, Quince had regained compliance with Nasdaq’s continued listing requirements under an alternative equity-based standard, closing the matter and stabilizing its trading status for investors.
The resolution of the Nasdaq compliance issue removed an immediate threat of delisting that could have curtailed liquidity and damaged shareholder confidence. By meeting the stockholders’ equity requirement instead of the market value threshold, Quince preserved its Global Market listing, which is critical for maintaining visibility in capital markets and supporting future financing and strategic options.
The most recent analyst rating on (QNCX) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Quince Therapeutics stock, see the QNCX Stock Forecast page.
Spark’s Take on QNCX Stock
According to Spark, TipRanks’ AI Analyst, QNCX is a Neutral.
The score is held down primarily by weak financial performance (no revenue, sustained losses, and significant ongoing cash burn) and bearish technicals (below 20/50-day averages with negative MACD). Corporate actions modestly support the outlook via added funding and pipeline assets, while Nasdaq listing compliance risk remains a material overhang; valuation screens low on P/E but is not enough to offset the core financial and trend risks.
To see Spark’s full report on QNCX stock, click here.
More about Quince Therapeutics
Quince Therapeutics, Inc. is a biotechnology company listed on the Nasdaq Global Market. The company operates in the life sciences sector and relies on access to public equity markets to fund its development activities and maintain compliance with stock exchange listing standards.
Average Trading Volume: 6,031,624
Technical Sentiment Signal: Sell
Current Market Cap: $17.6M
For an in-depth examination of QNCX stock, go to TipRanks’ Overview page.